ImmunityBio, Inc. (IBRX)
NASDAQ · Healthcare
ImmunityBio, Inc. EBITDA 2013–2025
ImmunityBio, Inc. annual/quarterly ebitda history and growth rate from 2014 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- ImmunityBio, Inc. ebitda for the quarter ending March 31, 2026 was -65.4 M, a 7.94% increase year-over-year.
- ImmunityBio, Inc. ebitda for the twelve months ending March 31, 2026 was -323.6 M, a 44.21% increase year-over-year.
- ImmunityBio, Inc. annual ebitda for 2025 was -240.5 M, a 26.37% decrease from 2024.
- ImmunityBio, Inc. annual ebitda for 2024 was -326.6 M, a 4.98% decrease from 2023.
- ImmunityBio, Inc. annual ebitda for 2023 was -343.7 M, a 3.21% increase from 2022.
- ImmunityBio, Inc. annual ebitda for 2022 was -333.0 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
ImmunityBio, Inc. EBITDA — FAQ
ImmunityBio, Inc. (IBRX) ebitda over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IBRX's ebitda history?
The chart and table above show ImmunityBio, Inc.'s ebitda by year and by quarter, including the growth rate.